Q3 2025 BioCryst Pharmaceuticals Inc Earnings Call Transcript
Key Points
- BioCryst Pharmaceuticals Inc (BCRX) reported strong revenue growth for Orladeo, with a 37% year-over-year increase, indicating robust demand and market acceptance.
- The company successfully closed the sale of its European business, which improved its financial position by enabling the repayment of PharmaCon debt and generating positive cash flow.
- BioCryst Pharmaceuticals Inc (BCRX) is making progress with its pipeline, including the BCX 17,725 program for Netherton syndrome, showing promising data from healthy volunteer studies.
- The company raised its Orladeo revenue guidance to between $590 and $600 million for the year, reflecting confidence in continued growth despite new competition.
- BioCryst Pharmaceuticals Inc (BCRX) announced a strategic acquisition of Austria Therapeutics, expected to strengthen its presence in the HAE market and drive double-digit growth into the 2030s.
- Enrollment for the BCX 17,725 program for Netherton syndrome is taking longer than planned, with early data now expected in Q1 next year.
- The company faces increased competition in the prophylaxis market, with new injectable products entering the market, although it maintains confidence in Orladeo's market position.
- BioCryst Pharmaceuticals Inc (BCRX) decided to de-emphasize its DME program due to focus and expense considerations, indicating potential challenges in resource allocation.
- The sale of the European business will result in a one-time drop in Q4 revenue, impacting short-term financial performance.
- The company is experiencing a typical decline in paid patient rates in the second half of the year, which may affect revenue growth momentum.
Good day and welcome to BioQuest Third quarter 2025 earnings conference call.
All participants will be in the lessly mode.
Should you need assistance, please signal a conference specialist by pressing the star key, followed by 0.
After today's presentation, there will be an opportunity to ask questions.
To ask a question, you may press start then one on the touchstone phone.
To withdraw a question, please press 2.
Please note this event is being recorded.
I would now like to turn the conference over to Nick Wilder. Please go ahead.
Good morning and welcome to BioCryst's 3rd quarter 2025 corporate update and financial results conference call. Participating with me today are CEO John Stonehouse, President and Chief Commercial Officer Charlie Geyer, Chief Development Officer Dr. Bill Sheridan, and Chief Financial Officer Barbara Gaz.
A press release and slide presentation about today's news are available on our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
